Dublin, Dec. 12, 2014 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/tl9lln/companion) has announced the addition of the "Companion Diagnostics in Personalized Medicine and Cancer Therapy" report to their offering.
Companion diagnostics (CDx) refers to a particular clinical diagnostic test that is under evaluation and is specifically linked to a known drug therapy. This linkage could be important in the therapeutic application and clinical outcome of a drug, such as with personalized medicine for oncology patients. The molecular diagnostics field plays a vital part in personalized medicine and has greatly expanded over the past twenty years, expanding by more than 20% annually compared to most other laboratory procedures.
Research will continue to produce an increased understanding of disease processes, and diagnostics manufacturers will continue to expand and refine the technology and automation needed for clinical testing. Companion diagnostics, although smaller at present, is one of the fastest growing segments in the in vitro diagnostic (IVD) market. And while the concept of a drug-diagnostic combination is not new, it has only recently started to generate interest with the move of healthcare towards pharmacogenomics.
This report examines the use of companion diagnostics in personalized medicine and cancer therapy. The study provides a qualitative and quantitative review of the industry, including cancer biomarker tests, pharmacogenomics tests, recurrence prediction tests, blood-based technologies, proteomics and regulatory trends.
Moreover, this analysis profiles the leading companies that are developing and manufacturing companion diagnostics solutions. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market share data are also included.
Key Topics Covered:
1. Overview
2. Companion Diagnostics and Personalized Medicine
3. Companion Diagnostics: Qualitative and Quantitative Market Analysis
4. Trends and Overview
5. Biomarker Tests Co-developed with Cancer Therapeutics as Companion Diagnostics
6. Business and Regulatory Trends in the Companion Biomarker Testing Sector
7. Companies Entering the Companion Diagnostics Market
Companies Mentioned:
- 20/20 GeneSystems
- AMDL
- Abbott Diagnostics
- Affymetrix
- Agendia BV
- Agensys
- Almac Group
- Arcturus Bioscience
- Aureon Biosciences
- Beckman Coulter
- BioCurex
- BioModa
- Biocode S.A.
- Biomarker Technologies
- Biomedical Diagnostics
- Biomerica
- Biomira
- Bruker Daltonics
- Byk Gulden
- Cangen Biotechnologies
- Caprion Proteomics
- Celera Diagnostics
- Cepheid
- Ciphergen Biosystems
- Clarient
- Claros Diagnostics
- Clinical Data: PGxHealth and Cogenics
- Correlogic Systems
- Cytogen
- Cytyc Corporation
- DRG International
- Dako
- DiaDexus LLC
- DiagnoCure
- Diagnostic Systems Laboratories
- Digene Corporation
- DxS
- EDP Biotech
- Epigenomics
- Exact Sciences Corporation
- Exagen Diagnostics
- Gen-Probe
- Gene Logic
- Genesis Genomics
- Genomic Health
- Health Discovery Corporation
- Ikonisys
- Immunicon
- Immunomedics
- Incyte Pharmaceuticals
- InterGenetics
- Ipsogen
- LabCorp
- Matritech
- Miraculins
- Mitsubishi Kagaku Medical
- Molecular Diagnostics (CytoCore)
- Monogram Biosciences
- Myriad Genetics
- NimbleGen Systems
- Northwest Biotherapeutics
- Oncotech
- Orion Genomics
- Oxford Genome Sciences
- Panacea Pharmaceuticals
- Perlegen Sciences
- Polymedco
- Power3 Medical Products
- Prometheus
- Proteome Systems
- Qiagen
- Sanko Junyaku
- SensiGen
- SuperArray Bioscience
- Third Wave Technologies
- Tosoh Medics
- TriPath Imaging
- TrimGen
- Upstream Biosciences
- Ventana Medical Systems
- Veridex
- bioMérieux
For more information visit http://www.researchandmarkets.com/research/tl9lln/companion